Medicine guide
Raptiva
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Efalizumab
- Made by
- Serono Europe Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Serono Europe Limited |
|---|---|
| Active substance | Efalizumab |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L04AA21 · Cancer treatments and immune-system medicines |
| Authorised on | 2004-09-20 |
| Last updated by the regulator | 2009-08-04 |
| EMA product number | EMEA/H/C/000542 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).